| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDA2 |
| Uniprot No | Q9GZX7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL |
| 预测分子量 | 28.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDA2重组蛋白的3篇代表性文献示例(注：内容为模拟概括，实际文献需根据具体研究检索)：
1. **文献名称**：*"Cloning and Functional Characterization of Recombinant Human CDA2 in Drug Resistance"*
**作者**：Wang X, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化重组人CDA2蛋白，证实其胞苷脱氨酶活性，并发现其在肿瘤细胞中对吉西他滨的代谢耐药性中起关键作用。
2. **文献名称**：*"Structural Analysis of CDA2 Reveals Substrate Binding Mechanisms"*
**作者**：Li Y, et al.
**摘要**：通过X射线晶体学解析重组CDA2蛋白的三维结构，揭示了其催化活性位点及底物结合模式，为设计抑制其活性的小分子药物提供依据。
3. **文献名称**：*"Recombinant CDA2 as a Biomarker for Pancreatic Cancer Prognosis"*
**作者**：Chen H, et al.
**摘要**：利用重组CDA2蛋白开发了一种新型ELISA检测方法，发现其在胰腺癌患者血清中高表达，且与吉西他滨化疗疗效呈负相关。
如需具体文献，建议通过PubMed或Web of Science以关键词“CDA2 recombinant protein”或“cytidine deaminase 2 expression”检索最新研究。
CDA2 (Cytidine Deaminase 2), also known as APOBEC2. is a member of the cytidine deaminase family, which plays critical roles in nucleotide metabolism, DNA/RNA editing, and immune regulation. This zinc-dependent enzyme catalyzes the deamination of cytidine to uridine in single-stranded DNA or RNA, a process implicated in diverse biological functions, including antibody diversification, viral defense, and epigenetic regulation. The human CDA2 gene is located on chromosome 6 and encodes a protein structurally characterized by a conserved catalytic domain with a zinc-coordinating active site.
Recombinant CDA2 protein is produced using biotechnological platforms, typically via expression in bacterial (e.g., *E. coli*) or mammalian cell systems. The recombinant form retains enzymatic activity and is purified to homogeneity for research and therapeutic applications. Its production often involves tagging (e.g., His-tag) to facilitate isolation and verification. Studies highlight its role in cancer biology, particularly in hematologic malignancies like acute myeloid leukemia (AML), where aberrant CDA2 expression correlates with disease progression and drug resistance. Additionally, CDA2 has garnered interest in mRNA vaccine development, as cytidine deamination can reduce immunostimulatory RNA motifs, enhancing vaccine safety.
Emerging applications include its use in gene-editing technologies to introduce targeted mutations when coupled with CRISPR systems. However, its dual role in genome stability—both protecting against viral integration and potentially contributing to mutagenesis—underscores the need for precise regulatory insights. Research on recombinant CDA2 continues to unravel its therapeutic potential as a biomarker or drug target, while its biochemical properties remain valuable for biotechnological innovations in nucleic acid engineering.
×
